Related Experiment Video

Updated: Sep 13, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating

Sonali Khanal1, Manjusha Pillai1, Md Shimul Bhuia2

  • 1School of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan, India.

Phytotherapy Research : PTR
|July 27, 2025
PubMed

Insights

Targeting the mechanistic target of rapamycin (mTOR) pathway is crucial for cancer treatment. Plant-derived bioactive compounds show promise in suppressing mTOR signaling, potentially leading to effective, personalized cancer therapies with fewer side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mechanistic target of rapamycin (mTOR) pathway is frequently deregulated in cancer, driving uncontrolled cell growth, proliferation, and survival.
  • This pathway's critical role in cancer pathogenesis makes it a significant therapeutic target.

Purpose of the Study:

  • To review plant-derived bioactive chemicals that target the mTOR signaling pathway in malignancies.
  • To explore the molecular mechanisms linking phytochemicals, mTOR signaling, and autophagy in cancer treatment.

Main Methods:

  • Literature review of studies investigating phytochemicals and their effects on the mTOR pathway.
  • Analysis of the role of mTOR signaling in cancer cell growth, proliferation, and survival.
  • Examination of the interplay between bioactive substances, mTOR, and autophagy.

Main Results:

  • Phytochemicals, including flavonoids and polyphenols, can suppress kinases within the PI3K/AKT/mTOR signaling cascade.
  • Targeting the mTOR pathway with plant-derived compounds offers a potential strategy for cancer therapy.

Conclusions:

  • Deregulation of the mTOR pathway provides a strong rationale for therapeutic intervention in cancer.
  • Personalized cancer treatments can be developed by studying the molecular connections between bioactive compounds, mTOR signaling, and autophagy.
  • Plant-derived chemicals targeting mTOR pathways represent a promising avenue for novel cancer drug development.
Keywords:
apoptosisautophagymTOR signaling pathwayoncologypharmacologyplant bioactive compounds

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

272

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K